-
Sector Analysis
Hepatitis C Virus: Epidemiology Report and Forecast to 2035
Hepatitis C is an inflammatory liver disease caused by the hepatitis C virus (HCV). HCV primarily spreads through direct blood contact, which can happen via needle/syringe sharing in people who inject drugs, unscreened blood transfusions and unsterilized medical equipment, and sexual contact involving blood. Additionally, vertical transmission of HCV can occur (Public Health England, 2018). Many people with hepatitis C are asymptomatic and unaware that they have the infection, with only approximately a quarter of patients exhibiting symptoms, including fatigue,...
-
Product Insights
Human Immunodeficiency Virus (HIV) Infections (AIDS): Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Human Immunodeficiency Virus (HIV) Infections (AIDS) - Global Clinical Trials Review, 2026" provides an overview of Human Immunodeficiency Virus (HIV) Infections (AIDS) Clinical trials scenario. This report provides top line data relating to the clinical trials on Human Immunodeficiency Virus (HIV) Infections (AIDS). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase,...
-
Product Insights
Hepatitis B: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Hepatitis B - Global Clinical Trials Review, 2026" provides an overview of Hepatitis B Clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatitis B. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Aspergillosis: Market View, Current and Future Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Aspergillosis Therapeutics. • In 2024 and 2029, India is anticipated to have the highest number of diagnosed incident cases of aspergillosis, representing a large portion of global cases. • Currently, the aspergillosis market is saturated with generic drugs. Triazoles, polyenes, and echinocandins are primarily used to manage aspergillosis. • The aspergillosis pipeline holds 37 molecules, with no assets in the pre-registration stage, four assets in Phase...
-
Product Insights
Malaria - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Malaria - Global Clinical Trials Review, 2026" provides an overview of Malaria Clinical trials scenario. This report provides top line data relating to the clinical trials on Malaria. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Cholera: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Cholera - Global Clinical Trials Review, 2025" provides an overview of Cholera Clinical trials scenario. This report provides top line data relating to the clinical trials on Cholera. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Thematic Analysis
Genomics: FutureTech Series
Genomic innovation is accelerating the transition to faster diagnostics, scalable biomanufacturing, and precision therapies. GlobalData’s latest FutureTech Series: Genomics report delivers a comprehensive analysis of the technologies redefining molecular healthcare. The report highlights automated DNA extraction, metagenomic pathogen detection, genome-edited iPSC therapies, plasmid DNA extraction kits, and isothermal DNA amplification, each positioned to address critical challenges in clinical reliability, decentralized testing, and therapeutic accessibility. Using GlobalData’s proprietary Tech Foresights platform, the report examines innovation drivers, challenges, patent leadership, and real-world...
-
Product Insights
Monkeypox: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Monkeypox - Global Clinical Trials Review, 2025" provides an overview of Monkeypox Clinical trials scenario. This report provides top line data relating to the clinical trials on Monkeypox. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Herpes Zoster (Shingles): Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Herpes Zoster (Shingles) - Global Clinical Trials Review, 2025" provides an overview of Herpes Zoster (Shingles) Clinical trials scenario. This report provides top line data relating to the clinical trials on Herpes Zoster (Shingles). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
Dermatophytosis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in dermatophytosis Therapeutics. India is projected to have the highest number of diagnosed prevalent cases of dermatophytosis in both 2024 and 2029, contributing 32.28% and 32.98% of cases, respectively. The dermatophytosis treatment market is largely saturated with generics, with antifungal agents comprising the majority of approved innovator drugs currently available. The pipeline for dermatophytosis remains limited, with no drug in the pre-registration stage, one drug in Phase...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.